For research use only. Not for therapeutic Use.
Antidiabetic; KATP channel blocker; the drug inhibits the sulfonylurea receptor 1 (SUR1), the regulatory subunit of the ATP-sensitive potassium channels (KATP) in pancreatic β cells
| Catalog Number | I047591 |
| CAS Number | 23047-14-5 |
| Molecular Formula | C23H26ClK2N3O5S |
| Purity | ≥95% |
| IUPAC Name | dipotassium;5-chloro-N-[2-[4-[(N-cyclohexyl-C-oxidocarbonimidoyl)sulfamoyl]phenyl]ethyl]-2-methoxybenzenecarboximidate |
| InChI | InChI=1S/C23H28ClN3O5S.2K/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18;;/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29);;/q;2*+1/p-2 |
| SMILES | COC1=C(C=C(C=C1)Cl)C(=NCCC2=CC=C(C=C2)S(=O)(=O)NC(=NC3CCCCC3)[O-])[O-].[K+].[K+] |
| Reference | F Tomai et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994, 90(2), 700-705.
A Marble. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents? Drugs 1971, 1(2), 109–115. |
